drugset / Trial / NCT00503594
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
Phase 2
Unknown
92 enrolled
Assistance Publique - Hôpitaux de Paris
French Innovative Leukemia Organisation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate two types of chemotherapy for primary central nervous system lymphoma in the elderly (age older than 60) : * Methotrexate, procarbazine, vincristine and cytarabine * Methotrexate and temozolomide
Timeline
- Start
- 2007-07
- Primary completion
- 2010-07
- Completion
- 2012-07
Publications
- Results Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus. 2006 Nov 15;21(5):E12. doi: 10.3171/foc.2006.21.5.13.
- Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrie M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cytarabine | Small molecule | 3 mg/m2 | — |
| Comparator | Methotrexate | Small molecule | 3.5 g | — |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | — |
| Comparator | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Comparator | procarbazine | Small molecule | 100 mg/m2 | — |